Glenmark stock tumbles to 52-week low on USFDA warning letter to Baddi unit
Plant accounts for 7 per cent of company's US sales; firm says no major pending approvals from unit in the next 12 months07-10-2019
07-10-2019
Glenmark receives USFDA warning for its Baddi facility
Drug firm Glenmark Pharmaceuticals on Saturday said it has received a warning letter from the US health regulator for its Baddi facility in Himachal05-10-2019
Glenmark Pharmaceuticals Ltd - 532296 - Update On The USFDA Inspection Of Glenmark'S Baddi Manufacturing Facility In Himachal Pradesh
We would like to inform you that in relation to an inspection conducted by USFDA between Apr 15 to 20, 2019 at the company's Baddi facility in HP,India,the company had earlier informed that the inspection was classified as 'Official Action Indicated' vide a letter by USFDA. With regards to the same inspection, USFDA has now issued a 'Warning Letter' to the Baddi facility. The company is committed to work along with USFDA to implement all the necessary corrective actions required to address the concerns raised in the letter & is in the process of preparing a detailed response to USFDA within 15 working days. We believe that the existing manufacturing & the sale of products from this facility will not be impacted. Baddi facility is expected to contribute USD 30mn in total sales for this FY which is approx 7% of total US sales.There are no major pending approvals from this facility in the next 12 months.There will be no financial impact on the organisation on account of this development.05-10-2019
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark receives approval from Russian Ministry of Healthcare to market Montlezir (Levocetirizine+Montelukast) film-coated tablets30-09-2019
Glenmark Pharma gets shareholders' nod to raise $200 million via debt securities
As per the proposal, Glenmark Pharma plans to raise up to $200 million in Indian and/or international market through bonds, debentures or other debt securities in one or more tranches28-09-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Glenmark Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here28-09-2019
Glenmark Pharmaceuticals Ltd - 532296 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
The 41st AGM of the Company was held on Friday, September 27, 2019 at 11.00 a.m. at Sunville Banquets & Conference Hall, 3rd floor, Dr. Annie Besant Road, Worli, Mumbai - 400 018 to transact the business as stated in the notice dated May 29, 2019, convening the AGM. In this regard, please find enclosed the following: 1. Summary of the proceedings of the AGM of the Company as required under Regulation 30, Para A of Schedule - III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (''Listing Regulations'') - Annexure A. 2. Voting results of the business transacted at the AGM, as required under Regulation 44 (3) of the Listing Regulations has been filed in XBRL Mode. 3. Report of the Scrutinizer pursuant to Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management and Administration) Rules, 2014 of today''s date - Annexure B. The Scrutinizer''s Report of today''s date is made available on the Company''s website at www.glenmarkpharma.com27-09-2019
Glenmark Pharmaceuticals Ltd - 532296 - Shareholder Meeting / Postal Ballot-Outcome of AGM
The 41st AGM of the Company was held on Friday, September 27, 2019 at 11.00 a.m. at Sunville Banquets & Conference Hall, 3rd floor, Dr. Annie Besant Road, Worli, Mumbai - 400 018 to transact the business as stated in the notice dated May 29, 2019, convening the AGM. In this regard, please find enclosed the following: 1. Summary of the proceedings of the AGM of the Company as required under Regulation 30, Para A of Schedule - III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ('Listing Regulations') - Annexure A. 2. Voting results of the business transacted at the AGM, as required under Regulation 44 (3) of the Listing Regulations has been filed in XBRL Mode. 3. Report of the Scrutinizer pursuant to Section 108 of the Companies Act, 2013 and Rule 20 of the Companies (Management and Administration) Rules, 2014 of today's date - Annexure B. The Scrutinizer's Report of today's date is made available on the Company's website at www.glenmarkpharma.com27-09-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals secures its position in the prestigious Dow Jones Sustainability Emerging Markets Index for the second year in a row26-09-2019
44 stocks hit 52-week lows on NSE
Among the stocks that touched their 52-week lows were Eveready Industries and Glenmark Pharmaceuticals.23-09-2019